Literature DB >> 22610781

Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.

Kate M Lewis1, Elizabeth Harford-Wright, Robert Vink, Alan J Nimmo, Mounir N Ghabriel.   

Abstract

It is not yet known how tumour cells traverse the blood-brain barrier (BBB) to form brain metastases. Substance P (SP) release is a key component of neurogenic inflammation which has been recently shown to increase the permeability of the BBB following CNS insults, making it a possible candidate as a mediator of tumour cell extravasation into the brain. This study investigated the properties of the BBB in the early stages of tumour cell invasion into the brain, and the possible involvement of SP. Male Wistar rats were injected with Walker 256 breast carcinoma cells via the internal carotid artery and euthanised at 1, 3, 6 and 9 days post tumour inoculation. Culture medium-injected animals served as controls at 1 and 9 days. Evidence of tumour cell extravasation across the BBB was first observed at 3 days post-inoculation, which corresponded with significantly increased albumin (p < 0.05) and SP immunoreactivity (p < 0.01) and significantly reduced endothelial barrier antigen labelling of microvessels when compared to culture medium control animals (p < 0.001). By day 9 after tumour cell inoculation, 100 % of animals developed large intracranial neoplasms that had significantly increased albumin in the peri-tumoral area (p < 0.001). The increased SP immunoreactivity and altered BBB properties at 3 days post-inoculation that coincided with early tumour invasion may be indicative of a mechanism for tumour cell extravasation into the brain. Thus, extravasation of tumour cells into the brain to form cerebral metastases may be a SP-mediated process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610781     DOI: 10.1007/s10585-012-9487-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  67 in total

Review 1.  Management of brain metastases.

Authors:  Riccardo Soffietti; Roberta Rudā; Roberto Mutani
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

2.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

Authors:  B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-04-07       Impact factor: 32.976

3.  Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells.

Authors:  M Ziche; L Morbidelli; M Pacini; P Geppetti; G Alessandri; C A Maggi
Journal:  Microvasc Res       Date:  1990-09       Impact factor: 3.514

4.  SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D.

Authors:  Wei-Qing Huang; Ji-Gang Wang; Lei Chen; Hong-Jun Wei; Hua Chen
Journal:  J Exp Clin Cancer Res       Date:  2010-05-24

5.  The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.

Authors:  Marisa Rosso; María Jose Robles-Frías; Rafael Coveñas; Manuel Vicente Salinas-Martín; Miguel Muñoz
Journal:  Tumour Biol       Date:  2008-09-09

6.  Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer.

Authors:  Helmut Friess; Zhaowen Zhu; Veronique Liard; Xin Shi; Shailesh V Shrikhande; Li Wang; Klaus Lieb; Murray Korc; Carla Palma; Arthur Zimmermann; Jean Claude Reubi; Markus W Büchler
Journal:  Lab Invest       Date:  2003-05       Impact factor: 5.662

7.  NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.

Authors:  Miguel Muñoz; Marisa Rosso; Francisco J Aguilar; Miguel A González-Moles; Maximino Redondo; Francisco Esteban
Journal:  Invest New Drugs       Date:  2007-09-29       Impact factor: 3.850

Review 8.  Brain-metastatic melanoma: a neurotrophic perspective.

Authors:  Dario Marchetti; Yvonne Denkins; Jane Reiland; Andrea Greiter-Wilke; Jennifer Galjour; Brian Murry; Jason Blust; Madhuchhanda Roy
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

9.  MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2.

Authors:  Odete Mendes; Hun-Taek Kim; Gina Lungu; George Stoica
Journal:  Clin Exp Metastasis       Date:  2007-05-16       Impact factor: 5.150

10.  Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.

Authors:  C Palma; M Bigioni; C Irrissuto; F Nardelli; C A Maggi; S Manzini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  12 in total

Review 1.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

3.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

4.  Why does melanoma metastasize into the brain? Genes with pleiotropic effects might be the key.

Authors:  Anatoliy I Yashin; Deqing Wu; Konstantin G Arbeev; Alexander M Kulminski; Eric Stallard; Svetlana V Ukraintseva
Journal:  Front Genet       Date:  2013-05-01       Impact factor: 4.599

5.  Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.

Authors:  Prema Robinson; Moses Kasembeli; Uddalak Bharadwaj; Nikita Engineer; Kris T Eckols; David J Tweardy
Journal:  Biomed Res Int       Date:  2016-02-11       Impact factor: 3.411

6.  Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours.

Authors:  Kate M Lewis; Elizabeth Harford-Wright; Robert Vink; Mounir N Ghabriel
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

7.  Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.

Authors:  Kate Marie Lewis; Renée Jade Turner; Robert Vink
Journal:  Int J Inflam       Date:  2013-05-29

8.  Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.

Authors:  Elizabeth Harford-Wright; Kate M Lewis; Mounir N Ghabriel; Robert Vink
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

9.  High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.

Authors:  Xiao-Yi Chen; Guo-Qing Ru; Ying-Yu Ma; Jun Xie; Wan-Yuan Chen; Hui-Ju Wang; Shi-Bing Wang; Li Li; Ke-Tao Jin; Xiang-Lei He; Xiao-Zhou Mou
Journal:  Onco Targets Ther       Date:  2016-06-16       Impact factor: 4.147

10.  Homotypic endothelial nanotubes induced by wheat germ agglutinin and thrombin.

Authors:  Lucia Pedicini; Katarina T Miteva; Verity Hawley; Hannah J Gaunt; Hollie L Appleby; Richard M Cubbon; Katarzyna Marszalek; Mark T Kearney; David J Beech; Lynn McKeown
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.